Replimune’s mission is to revolutionize cancer treatment with therapies designed to activate a powerful and durable full-body anti-tumor response, boldly transforming cancer care because patient’s lives depend on it. We imagine a world where cancer is a curable disease.
At Replimune, we live by our values:
United: We Collaborate for a Common Goal.
Audacious: We Are Bold and Innovative.
Dedicated: We Give Our Full Commitment.
Candid: We Are Honest With Each Other.
People are at the center of everything we do, and when it comes to our employees, we make it personal. With a deep sense of purpose, an innovative and collaborative culture, a competitive and forward-looking total rewards program, everyone at Replimune has a unique opportunity to contribute to the meaningful work we do which could impact the lives of patients.
Join us, as we reshape the future.
Job Summary:
This role provides cross-functional support for GxP activities as they relate to validation activities throughout the GxP organization. This position will provide comprehensive mentoring, oversight and monitoring of compliance for all applicable regulations spanning operations and IT relating to achieving and maintaining the validated state of facilities, utilities and equipment.
This position is based in our Framingham location and typically has a 5-day on-site expectation.
Key responsibilities:
Responsible for Quality oversight of validation and qualification activities ensuring accurate, consistent, and complete validation life cycle requirements are in place and followed throughout the GMP organization in Framingham. A critically important aspect of this role is application of validation best practices following FDA, ICH, NIST and PICS. Over time, data must be maintained across formats. This is a continual process involving various processes, rules, and standards.
Other responsibilities:
Education:
Required Experience:
About Replimune
Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of a novel portfolio of oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is designed to have a unique dual local and systemic activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor derived antigens and altering of the tumor microenvironment to ignite a strong and durable systemic response. The RPx product candidates are expected to be synergistic with most established and experimental cancer treatment modalities, leading to the versatility to be developed alone or combined with a variety of other treatment options. For more information, please visit www.replimune.com.
We are an Equal Opportunity Employer.
#LI-onsite
Software Powered by iCIMS
www.icims.com